Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer

Stanislaw Gluszek; Jarosław Matykiewicz; Urszula Grabowska; Magdalena Chrapek; Lukasz Nawacki; Iwona Wawrzycka; Martyna Gluszek-Osuch; Dorota Kozieł

doi:10.5114/ms.2020.94082

eISSN: 2300-6722
ISSN: 1899-1874

Medical Studies/Studia Medyczne

Current issue Archive Manuscripts accepted About the journal Supplements Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

1/2020
vol. 36

Send email

Copy url:

abstract:

Original paper

Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer

Stanislaw Gluszek

^{1, 2}

,

Jarosław Matykiewicz

¹

,

Urszula Grabowska

¹

,

Magdalena Chrapek

³

,

Lukasz Nawacki

¹

,

Iwona Wawrzycka

¹

,

Martyna Gluszek-Osuch

¹

,

Dorota Kozieł

¹

Collegium Medicum, Jan Kochanowski University, Kielce, Poland
Department of Clinic General Oncological and Endocrinological Surgery, Regional Hospital, Kielce, Poland
The Faculty of Mathematics and Natural Sciences, Jan Kochanowski University, Kielce, Poland

Medical Studies/Studia Medyczne 2020; 36 (1): 6–13

DOI: https://doi.org/10.5114/ms.2020.94082

Online publish date: 2020/03/31

View full text Get citation

PlumX metrics:

Introduction
Increased concentrations of pentraxin 3 (PTX 3) were diagnosed in acute pancreatitis (AP) and in pancreatic ductal adenocarcinoma (PDAC).

Aim of the research
To assess of the clinical usefulness of PTX3 in the early differentiation of AP from PDAC.

Material and methods
The test group consisted of 125 patients with AP and 24 people with PDAC, as well as 52 healthy subjects. The following concentrations were tested in plasma: PTX3, C-reactive protein (CRP), interleukin-6 (IL-6), and CA-19.9.

Results
The mean PTX3 concentration in the moderately-severe AP (MAP) or severe AP (SAP) equalled 16.53 ng/ml and was significantly higher in comparison with mild AP (9.60 ng/ml; p = 0.0007) and the control group (2.31 ng/ml). In the case of patients with PDAC, the mean concentration of PTX3 was 9.20 ng/ml and was significantly higher than in the control group (2.31 ng/ml); p < 0.0001. A significantly higher average CRP value of 100.37 mg/l and IL-6 91.65 pg/ml was also found in patients with PDAC compared to the control group (p < 0.0001). Tested pro-inflammatory cytokines were significantly higher in patients with MAP or SAP than in those with PDAC (p < 0.05). The ROC curve confirms the clear connection of PTX3 level and PDAC in comparison with the control group (p = 0.0001), relatively low sensitivity, and high specificity. However, the results were not significant enough to allow us to differentiate cancer from AP (p > 0.05).

Conclusions
Pentraxin 3 can be a marker in the prediction of the severe course of AP, but its clinical usefulness for the differentiation of PDAC was not confirmed.

keywords:

Clinical usefulness of pentraxin 3 (PTX3) as a biomarker of acute pancreatitis and pancreatic cancer

Stanislaw Gluszek 1, 2 , Jarosław Matykiewicz 1 , Urszula Grabowska 1 , Magdalena Chrapek 3 , Lukasz Nawacki 1 , Iwona Wawrzycka 1 , Martyna Gluszek-Osuch 1 , Dorota Kozieł 1

acute pancreatitis, pancreatic cancer, pentraxin 3

Stanislaw Gluszek

^{1, 2}

,

Jarosław Matykiewicz

¹

,

Urszula Grabowska

¹

,

Magdalena Chrapek

³

,

Lukasz Nawacki

¹

,

Iwona Wawrzycka

¹

,

Martyna Gluszek-Osuch

¹

,

Dorota Kozieł

¹